BOSTON, Dec. 17 /PRNewswire/ -- Scimitar Equity Research, Inc. issues a review on Nventa Biopharmaceuticals Corporation (TSX: NVN) entitled: "A Very Promising Therapeutic and Vaccine Candidate for the Treatment of Diseases Caused by the Human Papillomavirus (HPV)." The analyst research is available on Scimitar's website: http://www.scimitarequity.com.
About Nventa Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.
About HspE7, Nventa's Lead Product Candidate:
HspE7 is a novel therapeutic vaccine candidate for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Heat shock proteins (Hsps), also known as stress proteins, are naturally present in the human body and play important roles in the immune system, including transporting substances within cells and activating cells of the immune system.
Scimitar Equity Research, Inc. provides equity research of emerging
healthcare companies for the institutional and investment communities. We
certify that all the views expressed in this review, accurately reflect our
personal views about NVN.TO (TSX) and its or their securities. No part of
our compensation was, is, or will be, directly or indirectly, related to
the specific recommendations or views contained in this review and we will
not have any investment banking relationships or personal investment in any
sponsored company. Investors are advised that this analysis and review is
issued solely for informational purposes and is not to be construed as an
offer to sell or the solicitation of an offer to buy. Scimitar was paid for
preparing this review. This sponsored analysis and review does not have
regard to the specific investment objectives, financial situation and the
information contained herein is based on sources that we believe to be
reliable but is not guaranteed by us as being accurate and does not purport
to be a complete statement or summary of the available data. Any opinions
expressed are statements of our own judgment as of the date of publication
and are subject to change without notice. Please read all our important
Scimitar Equity Research, Inc.
Henry W. McCusker
Director of Research
phone: (617) 559.1080
fax: (617) 559.1083
|SOURCE Scimitar Equity Research, Inc.|
Copyright©2007 PR Newswire.
All rights reserved